SOX2 and glioma: Cyclopamine, an inhibitor of the SHH pathway, was also proved effective in reducing SOX2 expression and inducing cytotoxicity in in vitro studies, but unlike rapamycin, its combination with TMZ did not increase the sensitivity of glioma cells to chemotherapy (16).